Clinical Trials on Locally Advanced Prostate Cancer

Total 8574 results

AstraZeneca

Completed

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced or

Korea, Republic of
Lund University Hospital

Completed

A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (ARTSCANIII)

Locally Advanced Head and Neck Cancer

Sweden
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas

Unknown

Trastuzumab Optimization Trial in Breast Cancer (TOP)

Metastatic or Locally Advanced Breast Cancer

Italy
Exact Imaging

Completed

Urology of Virginia Case Series

Prostate Cancer | Prostatic Neoplasm | Cancer of the PROSTATE

United States
NRG Oncology
National Cancer Institute (NCI)

Suspended

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

Canada, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
University of Chicago
National Cancer Institute (NCI)

Completed

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

Stage II Prostate Carcinoma | Stage I Prostate Cancer

United States
MedSIR
AstraZeneca; Daiichi Sankyo, Inc.

Completed

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (RosHER)

Metastatic Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Spain
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditions

United States
St Vincent's University Hospital, Ireland

Recruiting

A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery

Locally Advanced Rectal Cancer | Pelvic Exenteration | Advanced Pelvic Malignancy

Ireland
Universitaire Ziekenhuizen KU Leuven

Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (SPARKLE)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate Cancer

Belgium
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University Health Network, Toronto

Completed

Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca (Cyto-Cog)

Breast Cancer | Locally Advanced Breast Cancer

Canada
AstraZeneca

Completed

Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (REMPRO)

Metastatic Castration-resistant Prostates Cancer

India, Peru, Saudi Arabia, Egypt, Colombia, Korea, Republic of, Turkey, United Arab Emirates
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Pharmavite LLC; Seafood Industry Research Fund

Active, not recruiting

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

Cancer Survivor | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Brander Beacons Cancer Research

Active, not recruiting

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

Cancer Survivor | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
University of Cincinnati

Unknown

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Castration-resistant Prostate Cancer | Cancer of the Prostate

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
Columbia University

Completed

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Breast Cancer | Locally Advanced Malignant Neoplasm

United States
University of California, Davis
Sanofi

Terminated

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Stage II Prostate Cancer | Adenocarcinoma of the Prostate

United States
GlaxoSmithKline

Completed

ARTS - AVODART After Radical Therapy For Prostate Cancer Study (ARTS)

Neoplasms, Prostate | Prostate Cancer After a Radical Treatment

Spain, Estonia, Netherlands, United Kingdom, Germany, Finland, France, Russian Federation, Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
MiraDX

Active, not recruiting

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial (GARUDA)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Jonsson Comprehensive Cancer Center

Recruiting

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy (EXCALIBUR)

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer

Stage IV Prostate Cancer AJCC v7 | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7 | Stage II Prostate Cancer AJCC v7

United States
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Australia, France, Germany, Italy, Singapore, United Kingdom
Novartis Pharmaceuticals

Terminated

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer (MBC) | Inoperable Locally Advanced Breast Cancer

France, Spain
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...

United States
British Columbia Cancer Agency

Recruiting

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

Canada
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC V7 | Stage IIA Prostate Cancer AJCC v7

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Northwestern University
Genzyme, a Sanofi Company

Withdrawn

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

PROSTATE CANCER

United States
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Tata Memorial Hospital

Terminated

Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer

Locally Advanced Breast Cancer and Large Operable Breast Cancer

India
Genta Incorporated

Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Non-resectable Breast Cancer

United States
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...

United States
AIO-Studien-gGmbH
Novartis Pharmaceuticals; iOMEDICO AG

Completed

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (VicTORia)

Her2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast Cancer

Germany
AstraZeneca

Completed

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer (EFECT)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Sweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
National Cancer Institute (NCI)

Terminated

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Prostate Neoplasms | Metastatic Castration Resistant Prostate Cancer

United States
ProteoMediX AG

Completed

PRospective Prostate biOmarker Study (PROPOSe)

Indication for Prostate Biopsy Due to Suspected Prostate Cancer

Austria, Germany, Denmark
University of Utah
National Cancer Institute (NCI)

Recruiting

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Centocor, Inc.

Terminated

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Cancer, Prostate

United States, United Kingdom, Belgium, Germany, Spain, France, Austria
Danish Head and Neck Cancer Group

Unknown

DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC

Radiotherapy | Locally Advanced Head and Neck Cancer | Hypoxic Radioresistance

Denmark

Clinical Trials on Locally Advanced Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations